April 6, 2026

Kidswell Bio Corporation (TSE:4584)

S-Quatre Corporation

Clinical Research Using SHED for Congenital Hypoganglionosis Selected by AMED grant

Tokyo,April 6, 2026 – S-Quatre Corporation, a subsidiary of Kidswell Bio Group, is engaged in the research and development of novel cell-based therapies (regenerative medicine products) using stem cells from human exfoliated deciduous teeth (SHED), with the aim of developing new treatments for pediatric and rare diseases for which no effective therapies currently exist.

A joint research proposal submitted with Kyushu University, titled *"Development of a Novel Therapeutic Approach for Congenital Isolated Hypoganglionosis Using SHED,"* has been selected for a grant under the Japan Agency for Medical Research and Development (AMED)'s FY2026 Project for Overcoming Childhood Diseases (Note 1). The principal investigator is Dr. Koichiro Yoshimaru, Lecturer in Department of Pediatric Surgery, Faculty of Medical Sciences, Kyushu University. S-Quatre will participate as a co-investigator.

This research aims to evaluate the safety and efficacy of autologous SHED administration in patients with congenital isolated hypoganglionosis (Note 2). SHED are known to secrete a wide range of growth factors and cytokines that promote neuronal growth, and are therefore expected to offer a novel therapeutic approach for this disease. Notably, this will be the first clinical research to administer SHED for congenital isolated hypoganglionosis.

In this research, S-Quatre will be responsible for the manufacturing and quality control of SHED, as well as providing its accumulated expertise in cell processing and clinical development.

Through this research, the Kidswell Bio Group aims to open new therapeutic possibilities for this disease, for which treatment options have been extremely limited, and to deliver meaningful treatment options to patients and their families as early as possible.

Note 1:

Selected projects under AMED – Program for Overcoming Childhood Diseases (FY2026)
https://www.amed.go.jp/koubo/03005/02/C_00004.html (only in Japanese)

Note 2:

Congenital isolated hypoganglionosis (Designated Intractable Disease No. 101) is a rare congenital disorder characterized by a deficiency of enteric ganglion cells, leading to severe impairment of intestinal motility and resulting in serious bowel obstruction. Currently, no established effective treatment exists.
Reference: Intractable Disease Information Center
https://www.nanbyou.or.jp/entry/3949 (only in Japanese)
